Dhoot Transmission IPO: Strong Listing Gains Expected

Dhoot Transmission and Molbio Diagnostics Initial Public Offerings (IPOs) opened for subscription on August 10, presenting investors with two distinct opportunities. Dhoot Transmission currently holds a notable edge for immediate listing gains, driven by its stronger Grey Market Premium (GMP).

Grey Market Premiums Diverge

Dhoot Transmission exhibits robust grey market momentum, maintaining a stable premium over the past week. This suggests sustained investor interest, positioning it favorably for strong debut performance.

• Dhoot Transmission GMP: Rs 259 per share
• Dhoot Transmission Estimated Listing Gain: Nearly 30%
• Molbio Diagnostics GMP: Rs 122 per share
• Molbio Diagnostics Estimated Listing Gain: About 15.1%

In contrast, Molbio Diagnostics has seen its grey market premium decrease, signaling a more conservative outlook for its initial market performance.

Financial Performance Snapshot

Assessing their financial fundamentals, Dhoot Transmission emerges as the larger entity by revenue and profit. The company has demonstrated significant growth over recent years.

• Dhoot Transmission FY26 Revenue: Rs 4,524.9 crore
• Dhoot Transmission FY26 Net Profit: Rs 396.8 crore
• Dhoot Transmission 3-Year Revenue CAGR: Approximately 27%
• Molbio Diagnostics FY26 Revenue: Rs 1,445.6 crore
• Molbio Diagnostics FY26 Net Profit: Rs 164.1 crore

Molbio Diagnostics, while smaller in scale, has consistently improved its revenue and profitability, underscoring its steady operational advancements.

Sector Leadership and Valuation

Dhoot Transmission is a dominant force in automotive electrical and electronics, holding nearly 70% market share in India’s electric two-wheeler and three-wheeler wiring harness sector. Molbio Diagnostics specializes in rapid molecular diagnostics, notably with its portable Truenat platform for tuberculosis and COVID-19, supported by government healthcare programs.

Both IPOs reflect reasonable valuations within their respective industries. Molbio Diagnostics’ pre-IPO P/E aligns with its listed diagnostic counterparts, while Dhoot Transmission’s valuation is comparable to other auto component firms.

• Molbio Diagnostics Pre-IPO P/E: 55.4 times
• Dhoot Transmission Pre-IPO P/E: 41.4 times

Identified Investment Risks

Molbio Diagnostics faces several operational risks, including its significant reliance on government and international aid-funded procurement. The company also derives a substantial portion of its revenue from tuberculosis products, and potential delays in regulatory approvals pose a concern.

Dhoot Transmission navigates risks associated with customer concentration and the inherent volatility of raw material prices. Furthermore, its performance remains susceptible to the cyclical nature of the broader automobile industry.

Investment Outlook

For investors prioritizing immediate listing gains, Dhoot Transmission presents the more favorable option, attributed to its higher and more stable Grey Market Premium. Long-term investors may also find Dhoot Transmission slightly advantageous due to its leadership in the expanding EV wiring harness market and robust financial metrics.

Molbio Diagnostics, conversely, remains an attractive consideration for those focused on the healthcare sector. Its niche technology and growth potential within diagnostics offer a compelling proposition despite different market signals.